Medtronic Stock Jumps 5% on Q1 Beat and Raised Guidance

Medtronic plc (NYSE: MDT) shares jumped as much as roughly 5–7% in pre-market trading on September 1, 2026, after the medical-device giant reported first-quarter fiscal 2027 results that topped Wall Street expectations and raised full-year outlook. Revenue reached $9.756 billion, up 13.7% both as reported and organically, while non-GAAP diluted EPS hit $1.45 versus the consensus of about $1.39. The company lifted its FY27 organic revenue growth guidance by 50 basis points to 7.25%–7.75% and non-GAAP EPS to $5.94–$6.00.

Medtronic Q1: $9.76B Revenue (+13.7%), $1.45 EPS, Guidance Lifted as Ablation Surges 88%

• Worldwide revenue of $9.756 billion rose 13.7% reported and organic, roughly 200 basis points above the midpoint of prior guidance. An extra selling week contributed an estimated $570 million to organic growth.
• GAAP diluted EPS was $1.14 (up 40.7%); non-GAAP diluted EPS was $1.45 (up 15.1%), ahead of the ~$1.39 consensus and prior guidance. GAAP net income reached $1.470 billion.
• Cardiovascular portfolio revenue hit $3.927 billion, up 19.5% reported and 18.9% organic. Cardiac Ablation Solutions surged 88%, Cardiac Rhythm Management grew 15%, with high-20s growth in Electrophysiology Therapies.
• Neuroscience revenue was $2.678 billion (+10.3% reported, +9.3% organic); Medical Surgical $2.279 billion (+10.0% reported, +10.2% organic); Diabetes $843 million (+16.9% reported, +14.9% organic).
• Management raised FY27 organic revenue growth guidance to 7.25%–7.75% (from 6.75%–7.25%) and non-GAAP EPS to $5.94–$6.00 (from $5.90–$6.00). FX impact is expected to be neutral to 1% accretive.
• Expanded CE Mark indication granted for the Affera Mapping and Ablation System with Sphere-9 Catheter to treat ventricular arrhythmias (including ventricular tachycardia and premature ventricular complexes). The system previously targeted atrial fibrillation; FDA Breakthrough Device Designation was also noted for the ventricular indication.
• Strategic moves announced the same day: ~$700 million partnership with Cornerstone Robotics (distribution rights for Sentire surgical system in select markets outside the U.S., complementing Hugo RAS) and up-to-$80 million investment in Pi-Cardia (leaflet-modification technology for complex TAVR, with exclusive distribution rights expected in 2027 and option to acquire).

MDT Jumps to $95–$99 Premarket from $90.65 as $1.45 EPS Beat and 88% Ablation Growth Drive Rally

The combination of a clear earnings beat, broad-based growth (especially the 88% Cardiac Ablation surge and strong Cardiovascular contribution), an upward guidance revision, and concurrent product/strategic catalysts outweighed a softer broader market (S&P 500, Dow, and Nasdaq trading lower pre-market). Premarket prices moved from the prior close of $90.65 into the mid-to-high $90s (reports showed levels near $95–$97.50 and highs approaching $99), reflecting investor confidence that Medtronic’s product cycle (Affera/PFA, Hugo robotics, and related platforms) is delivering faster commercial traction than many peers expected. Needham had already raised its price target to $114 from $101 (Buy) ahead of the print; broader consensus stood at a mean target of about $98.84 across ~29 analysts with a Buy tilt.

Medtronic Background: $36.4B FY26 Revenue (Strongest Growth in a Decade) as Ablation Hits $2B Run-Rate and Pipeline Expands

Medtronic, headquartered in Galway, Ireland, is a global leader in medical technology with a portfolio spanning cardiac devices, surgical robotics, diabetes care, and neuromodulation. Fiscal 2026 delivered the company’s strongest annual top-line growth in a decade ($36.4 billion revenue, +8.4% reported / +5.8% organic). Cardiac Ablation Solutions had already shown exceptional momentum (78% growth in Q4 FY26, annualizing near $2 billion). The medical-device sector faces competitive intensity in pulsed-field ablation, robotic surgery, and AI-enabled tools, yet Medtronic’s results and pipeline investments (Hugo, Affera expansions, Cornerstone, Pi-Cardia, recent Scientia Vascular and SPR Therapeutics deals) signal accelerating contribution from newer growth platforms. The 52-week range for MDT stood at $73.31–$106.33 prior to the move.

What’s Next: Ablation Momentum, Partnership Execution and Diabetes Separation

Investors will focus on the durability of Cardiovascular (especially PFA/ablation) and Medical Surgical momentum, execution of the Cornerstone and Pi-Cardia partnerships, progress on the planned Diabetes (MiniMed) separation, and any further pipeline updates (including additional Hugo indications and Affera U.S. ventricular data). The company hosts a webcast at 7:45 a.m. ET on September 1. Full-year guidance now embeds higher organic growth expectations; any early separation of the Diabetes business would prompt an update. Analyst commentary and follow-on rating/target changes are likely in the coming sessions.